Eleven Biotherapeutics Inc. (EBIO) Shares Up 12.9%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares shot up 12.9% during mid-day trading on Friday . The company traded as high as $4.87 and last traded at $4.55, with a volume of 5,339,037 shares. The stock had previously closed at $4.03.
The company’s market cap is $72.50 million. The firm has a 50-day moving average price of $2.99 and a 200 day moving average price of $1.36.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Equities analysts expect that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current fiscal year.
In related news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $2.74, for a total value of $2,855,080.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.